中文摘要：

目的检测慢性乙肝患者外周血单个核细胞α干扰素（IFN—α）的诱导表达及白细胞介素8（IL-8）表达，评价慢性乙肝患者外周血单个核细胞（PBMC）细胞免疫功能。方法PolyIC体外刺激正常对照组和慢性乙型肝炎病毒（Hepatitis Bvirus，HBV）感染组病人PBMC，取培养上清液利用病毒保护试验测定IFN—α2b治疗前后病人PBMC表达的干扰素抗病毒生物学活性。同时在IFN—α2b治疗前后，RT-PCR检测慢性乙肝患者不同干扰素应答组病人PBMCIL-8表达的变化。结果治疗前应答组病人（n=13）和无应答组病人（n=27）PBMC分泌的干扰素生物学活性显著低于正常对照组（n=20）（P〈0．01；P〈0．01）。应答组病人PBMC分泌的干扰素活性随治疗时间延长而增加，1个月时已显著高于无应答组病人（P〈0．01）；无应答组病人PBMC分泌的干扰素活性始终处于低下水平。治疗前，应答组病人和无应答组病人PBMCIL-8mRNA水平都显著高于正常对照组（均为P〈0．01）；治疗后，应答组病人IL-8水平随治疗时间延长而降低，1个月时已显著低于无应答组病人（P〈0．01），无应答组病人IL8水平始终处于较高水平。结论慢性HBV感染病人的细胞免疫功能受损，不能正常表达IFN-α但应答组病人经干扰素治疗后IFN—α表达能力逐渐恢复。慢性乙肝患者PBMCIL-8表达与肝脏炎症活动有关。慢性乙肝患者PBMCIFN—α活性检测结果也许可以作为干扰素治疗预后的判断指标。

英文摘要：

Objettive To detect expression of interferon-α（IFN-α） and interleukin 8 （IL-8） in peripheral blood mononuclear cells （PBMCs） of patients with chronic hepatitis B, and analysis cellular immune status of patients with chronic Hepatitis B virus （HBV） infection. Methods PBMCs of chronic HBV infection patients were cultured. Viral protection assay was used to detect antiviral biological activity of culture supernate from PBMC stimulated with high concentration of PolyIC. IL-8 mRNA from PBMC of patients with chronic hepatitis B was measured by reverse transeription-polymerase chain reaction （RT-PCR）. Results For responders （ n = 13 ）, the activity of IFN-α from PolyIC- stimulated PBMC was enhanced after treated with IFN-α2b, however, non-responders （ n = 27） continuously kept lower activity of IFN-α from PBMC during IFN-o2b therapy. The expression of IL-8 mRNA in PBMC of responder and non-responder were significantly higher than that of normal control group （ n = 20） before IFN-α2b therapy （ P 〈 0.01 ）. After treatment of IFN-α2b, the IL-8 level of responder decreased and level of IL-8 of non-responder kept high. Conclusion The cellular immune function of patients with chronic HBV is impaired. The expression of WN-α gene of the non-respanders of chronic HBV infected patients was inhibited. The level of IL-8 consists with liver inflammation. The IFN-α activity of PBMC perhaps can be a marker for hepatitis B prognosis after IFN- α therapy.